Research
Compare
Two to six companies, their latest annual figures side by side, from SEC filings.
AXIMAxim Biotechnologies, Inc.
| Figure | AXIMAxim Biotechnologies, Inc.FY2023 · Dec |
|---|---|
| Revenue | $39.52K |
| Revenue, yoy | +345.3% |
| Net income | $8.06M |
| Net income, yoy | −29.1% |
| Net margin | -20,395.0% |
| Free cash flow | $1.03M |
| FCF margin | -2,607.7% |
| EPS, diluted | $0.04 |
Add another company.
Annual · FY2019–FY2023 · USD
From SEC EDGARSame fiscal periods, as filed